Product-information templates - Human
Table of contents
The European Medicines Agency's (EMA) Working Group on Quality Review of Documents (QRD) develops, reviews and updates templates for product information for use by applicants and marketing authorisation holders for human medicines.
The information contained in these documents is non-exhaustive. Companies should refer to all relevant European Union legislation and guidelines when drawing up applications. It is the company's responsibility to ensure that the product information complies with all such requirements.
Compliance with QRD template v10.3
QRD template v10.3 has been revised in September 2022 solely* to include guidance in Annex II section C for conditional marketing authorisations.
Any new marketing authorisation granted via the centralised procedure as a conditional marketing authorisation must comply with the revised QRD template v10.3. Ongoing marketing authorisation applications must align their product information to the revised QRD template v10.3 as early as possible, and by Day 181 of the procedure at the latest.
Holders of existing conditional marketing authorisations granted via the centralised procedure must update the product information annexes with the next regulatory procedure affecting the product information, and at the latest with the annual renewal, to comply with the revised QRD template.
Since 28 June 2019, applicants need to complete Annex II and present a draft of this together with the summary of product characteristics (SmPC), labelling and package leaflet when submitting the product information annexes as part of their marketing authorisation application.
*Additional linguistic corrections in the Czech, Danish, German, Estonian, Hungarian, Italian, Lithuanian and Slovenian language templates have been implemented.
New Guideline on Core SmPC, Labelling and Package Leaflet for advanced therapy medicinal products (ATMPs) containing genetically modified cells.
This new guideline provides a template for ATMPs containing genetically modified cells which is made available in English and all the other EU languages.
Any new marketing authorisation granted via the centralised procedure for ATMPs containing genetically modified cells must comply with the guideline. Ongoing marketing authorisation applications must align their product information as early as possible, and by Day 181 of the procedure at the latest.
Holders of existing marketing authorisations granted via the centralised procedure for ATMPs containing genetically modified cells must update the product information annexes with the next regulatory procedure affecting the product information.
-
List item
QRD product-information annotated template (English) version 10.3 (PDF/766.95 KB)
First published: 03/12/1997
Last updated: 28/09/2022
10.3 -
List item
QRD product-information annotated template (English) version 10.3 - highlighted (PDF/768.17 KB)
First published: 03/12/1997
Last updated: 28/09/2022
10.3 -
List item
QRD product-information template version 10.3 (DOCX/69.1 KB)
First published: 03/12/1997
Last updated: 28/09/2022
10.3 -
-
List item
QRD product-information template version 10.3 - highlighted (PDF/569.36 KB)
First published: 28/06/2019
Last updated: 28/09/2022
10.3 -
-
List item
QRD annex A template (DOCX/33.89 KB)
First published: 19/06/2009
Last updated: 28/06/2019 -
-
List item
QRD annex related to the Article-127a template (DOCX/19 KB)
First published: 08/10/2012
Last updated: 28/06/2019 -
-
List item
QRD annex IV conditional positive template (DOCX/14.86 KB)
First published: 08/10/2012
Last updated: 28/06/2019 -
-
List item
QRD annex IV exceptional circumstances positive template (DOCX/14.81 KB)
First published: 08/10/2012
Last updated: 28/06/2019 -
-
List item
QRD annex IV standard positive template (DOCX/21.17 KB)
First published: 08/10/2012
Last updated: 28/06/2019 -
-
List item
QRD PSUR annex IV template (DOCX/21.39 KB)
First published: 19/03/2014
Last updated: 28/06/2019 -
-
List item
Implementation plan for the introduction of the safety features on the packaging of centrally authorised medicinal products for human use (PDF/57.88 KB)
First published: 09/02/2016
Last updated: 05/07/2017
EMA/785582/2014 rev.1 -
List item
Policy on combined Summaries of Product Characteristics (SmPCs) (PDF/84.35 KB)
First published: 10/06/2015
Last updated: 10/06/2015
EMA/333423/2015
-
List item
Guideline on core SmPC, Labelling and Package Leaflet for advanced therapy medicinal products (ATMPs) containing genetically modified cells (PDF/465.69 KB)
Adopted
First published: 26/10/2022
EMA/CAT/CHMP/158266/2021 -
List item
ATMP product information template version 1 (DOCX/75.47 KB)
First published: 28/09/2022 -
Mutual-recognition, decentralised, referral and PSUR single assessment (PSUSA) (Nationally Authorised Products only) procedures
-
List item
Mutual-recognition decentralised referral product information template (English) version 4.2 (PDF/206.39 KB)
First published: 28/04/2021 -
List item
Mutual-recognition, decentralised and referral product-information template version 4.2 (DOCX/41.62 KB)
First published: 30/08/2011
Last updated: 26/04/2021 -
-
List item
PSUSA nationally authorised products template (DOCX/22.2 KB)
First published: 15/09/2015
Last updated: 28/06/2019 -
- Committee for Mutual Recognition and Decentralised Procedures - Human: Annotated Quality Review of Documents template for mutual-recognition and decentralised procedures and specific addendum for (traditional) herbal medicinal products
-
Practical information on translations for referral procedures (human)
-
List item
QRD Appendix I - Statements for use in section 4.6 'pregnancy and lactation' of the summary of product characteristics (DOC/38.5 KB)
First published: 01/07/2008
Last updated: 05/11/2009 -
-
List item
QRD Appendix II - Medical Dictionary for Regulatory Activities terminology to be used in section 4.8 'undesirable effects' of the summary of product characteristics (Cover page) (DOCX/113.67 KB)
First published: 27/06/2018
Last updated: 08/09/2022
EMA/295934/2018 v.5 -
List item
QRD Appendix II - Medical Dictionary for Regulatory Activities terminology to be used in section 4.8 'undesirable effects' of the summary of product characteristics (DOCX/19.16 KB)
First published: 01/07/2009
Last updated: 09/06/2022 -
-
List item
QRD Appendix III to the Quality Review of Documents templates for human medicinal products (Cover page) (DOC/113.62 KB)
First published: 31/07/2008
Last updated: 08/12/2021
EMEA/29277/2003 v.5 -
List item
QRD Appendix III to the Quality Review of Documents templates for human medicinal products (DOC/33 KB)
First published: 09/02/2016
Last updated: 09/02/2016 -
-
List item
QRD Appendix IV - Terms and abbreviations for batch number and expiry date to be used on the labelling of human medicinal products (PDF/139.15 KB)
First published: 01/07/2008
Last updated: 08/12/2021
EMA/286379/2019 Rev.14 -
List item
QRD Appendix V - Adverse-drug-reaction reporting details (DOCX/134.15 KB) (updated)
First published: 15/03/2013
Last updated: 16/05/2023
EMA/67830/2013, Version 26
- Guideline on Nordic packages - Questions and answers
- List of standard terms for pharmaceutical dosage forms, routes of administration and containers
- Interinstitutional style guide
- Guideline on summary of product characteristics revision 2
- Guideline on the packaging information of medicinal products for human use authorised by the Community
- Guideline on the readability of the labelling and package leaflet of medicinal product for human use (incl. Braille requirements, see Chapter 2)
- Medical Dictionary for Regulatory Activities (MedDRA)